Epigenetics refers to
the covalent modification of DNA, RNA, or protein that results in changes to
the function and/or regulation of these molecules, without altering their
primary sequences. These modifications can occur naturally, or can be
influenced, by several factors including age, environment, disease state, and
changes in lifestyle.
Expanding application areas of epigenetics in non-oncology diseases,
personalized medicine, and target therapy are expected to provide growth
opportunities for players operating in the epigenetics market in the coming
years. The growth in this market is primarily attributed to decreasing
sequencing costs, increasing research activity, funding for epigenetics
research, rising prevalence of cancer and growing applications of epigenetics
in non-oncology diseases.
Epigenetic changes such as dysregulation of DNA methylation are associated with
cancer development and progression. Epigenetics provides new opportunities for
deriving therapeutic strategies designed to reverse dysregulation in cancer.
Several cancer research studies that utilize epigenetics techniques are
currently underway; significant investments are being made to support these
researches. The increasing prevalence of cancer will drive epigenetics research
focused on this condition, which will drive growth in epigenetics market.
The global epigenetics market is projected to reach USD 1.60 billion by 2022
from USD 0.85 billion in 2016, at a CAGR of 13.3%.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896
Applications of Epigenetics Market:
# Oncology
# Metabolic Diseases
# Developmental Biology
# Immunology
# Cardiovascular Diseases
Oncology is one of those applications where epigenetics technology is
extensively used for deriving therapeutic strategies designed to reverse
transcriptional abnormalities inherent to the cancer epigenome. The disruption
of epigenetic modifications, such as DNA methylation and histone modification,
results in altered gene function or expression and cellular transformation
leading cancer. Epigenetics assists in the development of inhibitors of DNA
methyltransferases and histone deacetylases (HDACs), which have been found to
be clinically effective in cancer treatment, attesting to the value of
epigenetic therapies in oncology.
Major Market Developments:
1. In July 2017, Agilent launched AriaDx Real-Time PCR System
2. In June 2017, Illumina launched Extended RAS Panel, a NGS kit
3. In January 2017, Illumina entered into an agreement with Koninklijke Philips
(Netherlands) to integrate Ilumina’s sequencing systems with Philips’
IntelliSpace Genomics clinical informatics platform for oncology.
Regional Analysis of Epigenetics Market:
The epigenetics market in Asia-Pacific region is expected to witness the
highest CAGR during the forecast period of 2017 to 2022. The growth of this
segment can be attributed to the increasing R&D spending, increasing
government initiatives, and rising focus on key market players in the region.
Emerging markets such as Brazil, China, and India offer significant growth
potential to market players.
Request Sample Report Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=896
This can primarily be attributed to the diversified healthcare market in this
region, growing incidence of infectious and chronic disorders, and increasing
R&D initiatives targeted at the development of innovative genomic
techniques. In addition, developments in research infrastructure, increasing
R&D expenditure, low labor cost, and rapid growth in the number of CROs and
pharmaceutical industry are encouraging market players to invest in these
countries.
Key Players In Epigenetics Market:
The prominent players of this market are Illumina (US), Thermo Fisher (US),
Diagenode (Belgium), QIAGEN (Netherlands), Merck Millipore (US), Abcam (UK),
Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US),
PerkinElmer (US), Bio-Rad (US).
